IMAI Medtech

Summary

About

About IMAI Medtech

IMAI Medtech develops automated three-dimensional histology for cancer diagnostics and biomedical research. Its platform processes intact tissue, applies staining, captures volumetric images and reconstructs digital models so pathology teams can examine tumour margins and spatial structures beyond the limited view provided by individual thin sections.

Automation standardises preparation and imaging across samples, while analysis software supports navigation through the reconstructed tissue volume. The Zurich company is developing instruments, consumables and computational workflows for laboratories and clinical pathology. Adoption depends on validation and regulatory requirements for each diagnostic use, with current work centred on translating the platform into routine laboratory processes.

PRICE
Range 1Y
Return
High
Low
Updated
DATA: KORTHOS

Team

  • Robert McGinn - Co-Founder - Co-founded IMAI's automated three-dimensional histology platform.

Timeline

Events

  • 2024-06-17 - Award - IMAI receives Venture Kick programme support

    The support will advance hardware prototypes towards design freeze and further develop image-analysis software. The platform combines automated tissue processing and cancer-detection labelling with cell counting and three-dimensional visualisation. The company plans to target biomedical research laboratories before entering clinical pathology after medical certification.

    Source

Context

Comparable profiles

Shared workflows

Context tags

  • Lab automation platform builder - Stack Layer - Lab automation platform builder is a documented company focus.
  • Medical robot OEM - Stack Layer - Medical robot OEM is a documented company focus.
  • Lab automation handling - Workflow - Lab automation handling is a documented company focus.